Effects of the cessation of mass screening for neuroblastoma at 6 months of age: A population-based study in Osaka, Japan

Journal of Epidemiology

Volumn 26, Issue 4, 2016, Pages 179-184

  Ioka, Akiko ^a   Inoue, Masami ^b   Yoneda, Akihiro ^c   Nakamura, Tetsuro ^c   Hara, Junichi ^c   Hashii, Yoshiko ^d   Sakata, Naoki ^e   Yamato, Kazumi ^f   Tsukuma, Hideaki ^a   Kawa, Keisei ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cessation; Incidence; Mortality; Neuroblastoma; Screening

Indexed keywords

ADOLESCENT; CHILD; EVALUATION STUDY; FEMALE; HUMAN; INCIDENCE; INFANT; JAPAN; MALE; MASS SCREENING; MORTALITY; NEUROBLASTOMA; NEWBORN; PRESCHOOL CHILD; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; JAPAN; MALE; MASS SCREENING; MORTALITY; NEUROBLASTOMA; REGISTRIES;

EID: 84963600295     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20150054     Document Type: Article

References (27)

1. Baba S, Ioka A, Tsukuma H, Noda H, Ajiki W, Iso H. Incidence and survival trends for childhood cancer in Osaka, Japan, 1973-2001. Cancer Sci. 2010;101:787-92.
2. Takeuchi LA, Hachitanda Y, Woods WG, Tuchman M, Lemieux B, Brisson L, et al. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project. Cancer. 1995;76:2363-71.
3. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan. Cancer Causes Control. 1998;9: 631-6.
4. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041-6.
5. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047-53.
6. Honjo S, Doran HE, Stiller CA, Ajiki W, Tsukuma H, Oshima A, et al. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening. Int J Cancer. 2003;103:538-43.
7. Katanoda K, Hayashi K, Yamamoto K, Sobue T. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan. J Epidemiol. 2009;19:266-70.
8. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350:2010-1.
9. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209-14.
10. Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, et al. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment. Pediatr Surg Int. 2004;20: 27-32.
11. Fritsch P, Kerbl R, Lackner H, Urban C. "Wait and see" strategy in localized neuroblastoma in infants: an option not only for cases detected by mass screening. Pediatr Blood Cancer. 2004;43:679-82.
12. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. Cancer Incidence in Five Continents, Vol. X. IARC Scientific Publication No. 164. Lyon: International Agency for Research on Cancer; 2013.
13. Parkin DM, Kramarova E, Draper GJ, Masuyer E, Michaelis J, Neglia J, et al. International Incidence of Childhood Cancer vol.2. IARC Scientific Publications No. 144. Lyon: International Agency for Research on Cancer; 1998.
14. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer. 2000;36:901-8.
15. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011;47:561-71.
16. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:581-91.
17. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260-8.
18. Berthold F, Trechow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases. Am J Pediatr Hematol Oncol. 1992;14:207-15.
19. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256-64.
20. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77.
21. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-81.
22. Castleberry RP, Shuster JJ, Smith EI. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol. 1994;12:2378-81.
23. Ikeda H, Iehara T, Tsuchida Y, Kaneko M, Hata J, Naito H, et al. Experience with International Neuroblastoma Staging System and Pathology Classification. Br J Cancer. 2002;86:1110-6.
24. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer Registration: Principles and Methods. IARC Scientific Publications No. 95. Lyon: International Agency for Research on Cancer; 1991.
25. StataCorp. Stata Statistical Software: Release 12.0. Texas: Stata Corporation; 2011.
26. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al; EUROCARE Working Group. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a populationbased study. Lancet Oncol. 2014;15:35-47.
27. Pui CH, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT, et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol. 2012;30: 2005-12.